Investing in Jasper Therapeutics Inc. (JSPR): What You Must Know


In a filing, Jasper Therapeutics Inc. revealed its 10% Owner Carlyle Group Inc. acquired Company’s shares for reported $4.7 million on Jan 27. In the deal valued at $1.50 per share,3,133,333 shares were bought. As a result of this transaction, Carlyle Group Inc. now holds 8,761,891 shares worth roughly $ 15.42 million.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Then, ROCHE HOLDING LTD sold 75,000 shares, generating $141,750 in total proceeds. Upon selling the shares at $1.89, the 10% Owner now owns 4,549,606 shares.

Before that, Lis William sold 24,743 shares. Jasper Therapeutics Inc. shares valued at $51,404 were divested by the Director at a price of $2.08 per share. As a result of the transaction, Lis William now holds 40,486 shares, worth roughly $71255.36.

Cantor Fitzgerald initiated its Jasper Therapeutics Inc. [JSPR] rating to an Overweight in a research note published on Friday, February 28, 2022; the price target was $10. PT values the company’s stock at a premium of 82.4 to its Friday closing price. A number of analysts have revised their coverage, including Credit Suisse’s analysts, who began to cover the stock in early November with a ‘”an Outperform”‘ rating. William Blair began covering JSPR with “an Outperform” recommendation on October 21, 2021. BMO Capital Markets started covering the stock on October 20, 2021. It rated JSPR as “an Outperform”.

Price Performance Review of JSPR

On Friday, Jasper Therapeutics Inc. [NASDAQ:JSPR] saw its stock jump 1.15% to $1.76. On the same session, the stock had its day’s lowest price of $1.70, but rose to a high of $1.775. Over the last five days, the stock has lost -3.83%. Jasper Therapeutics Inc. shares have risen nearly 264.46% since the year began. Nevertheless, the stocks have fallen -53.87% over the past one year. While a 52-week high of $4.62 was reached on 01/03/23, a 52-week low of $0.39 was recorded on 01/06/23. SMA at 50 days reached $1.4800, while 200 days put it at $1.6113. A total of 0.52 million shares were traded, compared to the trading of 1.07 million shares in the previous session.

Levels Of Support And Resistance For JSPR Stock

The 24-hour chart illustrates a support level at 1.7150, which if violated will result in even more drops to 1.6700. On the upside, there is a resistance level at 1.7900. A further resistance level may holdings at 1.8200. The Relative Strength Index (RSI) on the 14-day chart is 52.46, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0427, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 66.67%. Stochastics %K at 33.88% indicates the stock is a holding.

How much short interest is there in Jasper Therapeutics Inc.?

A steep rise in short interest was recorded in Jasper Therapeutics Inc. stocks on Jan 30, 2023, growing by 1.08 million shares to a total of 1.34 million shares. Yahoo Finance data shows the prior-month short interest on Dec 29, 2022 was 0.26 million shares. There was a rise of 80.68%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 1.46% of the overall stock float, the days-to-cover ratio (short ratio) rose to 0.14.

Jasper Therapeutics Inc. [JSPR] – Who Are The Largest Shareholders?

In filings from BVF Partners LP, it is revealed that the company now owns 9,900,000 shares, or roughly 9.06% of the outstanding JSPR shares. Additionally, Velan Capital Investment Manageme increased 160.48% of its stake after which the total value it holdings stand at $14,254,500. At present, The Vanguard Group, Inc. is holding 530,438 shares valued at $0.9 million. Fernwood Investment Management LL owned 454,706 shares of the company at the time of its most recent 13F filing, worth $0.77 million.

The most recent change occurred on October 13, 2021 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $21 price target.


Please enter your comment!
Please enter your name here